SyntheticMR AB resolves on a fully secured rights issue of approximately SEK 32.8 million

SyntheticMR AB's board has resolved, subject to an extraordinary general meeting on 9 January 2026, a fully secured rights issue of approximately SEK 32.8 million at a subscription price of SEK 1.10 per share (2 subscription rights per new share), with a record date of 16 January 2026 and a subscription period of 20 January–3 February 2026. The issue is secured 100% via subscription commitments (≈SEK 10.3m, ~31.5%) from board and management and a SEK 22.4m (~68.5%) guarantee from largest shareholder Staffan Persson/Swedia Invest AB; full subscription would increase shares by up to 29,777,342 (dilution ≈33.33%). Proceeds will fund commercial scaling (direct and OEM sales), product integration including ARIA support, marketing and working capital as SyntheticMR shifts from integration to commercial execution; an information document is expected ~19 January 2026.

Analysis

Market structure: The fully‑underwritten SEK 32.8m rights issue (SEK1.10/share, 2 rights → 1 share) materially rebalances ownership and funds a 12–18 month commercial acceleration. Winners: SyntheticMR (commercial runway, ARIA product optionality), Swedia Invest/Staffan Persson (can reach ~50.2% voting control), Combinostics product lines and OEM partners. Losers: non‑participating minority holders (≈33% dilution if you don't subscribe) and small-cap peers facing tougher OEM competition.

Risk assessment: Near‑term binary events are the EGM (9 Jan), record date (16 Jan) and subscription window (20 Jan–3 Feb); failure of EGM or conditional exemption could cancel or delay funding. Tail risks include guarantee non‑cash/default (guarantee not bank‑backed), ARIA regulatory setbacks, or US market execution failure — any of which could halve revenue projections in 12–24 months. Hidden dependency: revenue scaling relies on converting OEM technical integrations into recurring contracts within 12 months; slippage magnifies cash burn quickly.

Trade implications: If you can subscribe, the most favorable asymmetric payoff is to participate at SEK1.10 and hold 12–18 months — insiders underwriting 100% reduces placement risk but not execution risk. If unable/unwilling to hold equity, a long‑equity + protective put (3–6 month, ~20% OTM) or a call‑spread (if liquid) captures upside while capping downside. Relative trade: go long SyntheticMR (Spotlight small‑cap healthcare software) vs short a basket of non‑recurring‑revenue Spotlight medtechs (net exposure long 1–2% of portfolio).

Contrarian angle: Markets may underprice execution risk — insider underwriting can be read as confidence but also as opportunistic control consolidation; mandatory bid exemption conditions are fragile and could trigger governance risk. Historical analogues: Nordic small‑cap rights issues often produce an initial pop then flat performance for 6–12 months absent OEM contract announcements; watch for immediate post‑issue churn and insider accumulation above 30% as a negative signaling event.

Key Decisions for Investors

• If comfortable holding 12–18 months, subscribe pro rata in the Rights Issue at SEK1.10 to establish a 2–3% portfolio position in SyntheticMR (Spotlight‑listed). Take partial profits if share price ≥ SEK1.60 within 3 months or fully re‑evaluate if price ≥ SEK2.00 within 12 months; hard stop‑loss: sell if post‑issue price < SEK0.90 within 30 trading days.
• If you prefer a hedged exposure, acquire equity via the Rights Issue and simultaneously buy a 3‑6 month put ~20% OTM sized 30–50% of the equity position to cap downside; if options are unavailable, use a 3‑6 month call‑spread (buy nearer‑term ITM, sell OTM) sized to 1–2% portfolio risk.
• Implement a pair trade: long SyntheticMR (via rights or market) and short a basket of Spotlight small‑cap medtech/health‑IT companies without recurring revenue (target short = 50% notional of long) to isolate execution/recurring‑revenue thesis; rebalance after Q4 report on 6 Feb 2026.
• Reserve 1–2% cash to deploy within 5 trading days post‑Q4 report (6 Feb 2026): if Q4 shows ≥20% YoY recurring revenue growth and management guides +12 months of OEM contract rollouts, top up long to 4–5%; if Q4 misses and insider ownership rises >40% without clear governance safeguards, reduce exposure to zero.